Literature DB >> 11689673

An N-terminal domain of herpes simplex virus type Ig E is capable of forming stable complexes with gI.

S M Rizvi1, M Raghavan.   

Abstract

Using limited proteolytic analyses, we show that gE present in soluble herpes simplex virus type 1 gE-gI complexes is cleaved into a C-terminal (CgE) and an N-terminal (NgE) domain. The domain boundary is in the vicinity of residue 188 of mature gE. NgE, but not CgE, forms a stable complex with soluble gI.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11689673      PMCID： PMC114778          DOI： 10.1128/JVI.75.23.11897-11901.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  18 in total

1.  The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18.

Authors:  T L Chapman; A P Heikeman; P J Bjorkman
Journal:  Immunity       Date:  1999-11       Impact factor: 31.745

2.  Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G.

Authors:  T L Chapman; I You; I M Joseph; P J Bjorkman; S L Morrison; M Raghavan
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

3.  Pairing of the nucleotide binding domains of the transporter associated with antigen processing.

Authors:  P E Lapinski; G G Miller; R Tampé; M Raghavan
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

4.  Herpes simplex virus IgG Fc receptors induced using recombinant adenovirus vectors expressing glycoproteins E and I.

Authors:  T Hanke; F L Graham; V Lulitanond; D C Johnson
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

Review 5.  Glycoprotein E of pseudorabies virus and homologous proteins in other alphaherpesvirinae.

Authors:  L Jacobs
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

6.  Herpes simplex virus type 1 encodes two Fc receptors which have different binding characteristics for monomeric immunoglobulin G (IgG) and IgG complexes.

Authors:  G Dubin; I Frank; H M Friedman
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Induction of immunoglobulin G Fc receptors by recombinant vaccinia viruses expressing glycoproteins E and I of herpes simplex virus type 1.

Authors:  S Bell; M Cranage; L Borysiewicz; T Minson
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

8.  The extracellular part of glycoprotein E of bovine herpesvirus 1 is sufficient for complex formation with glycoprotein I but not for cell-to-cell spread.

Authors:  J Tyborowska; K Bieńkowska-Szewczyk; M Rychłowski; J T Van Oirschot; F A Rijsewijk
Journal:  Arch Virol       Date:  2000       Impact factor: 2.574

9.  Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI.

Authors:  D C Johnson; M C Frame; M W Ligas; A M Cross; N D Stow
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

10.  Specificity of Fc receptors induced by herpes simplex virus type 1: comparison of immunoglobulin G from different animal species.

Authors:  P J Johansson; E B Myhre; J Blomberg
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103
View more
  12 in total

1.  Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection.

Authors:  Barbara Berarducci; Minako Ikoma; Shaye Stamatis; Marvin Sommer; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Responses of herpes simplex virus type 1-infected cells to the presence of extracellular antibodies: gE-dependent glycoprotein capping and enhancement in cell-to-cell spread.

Authors:  Syed Monem Rizvi; Malini Raghavan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo.

Authors:  John M Lubinski; Helen M Lazear; Sita Awasthi; Fushan Wang; Harvey M Friedman
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

4.  Induction of Rod-Shaped Structures by Herpes Simplex Virus Glycoprotein I.

Authors:  Wuchao Zhang; Peng Gao; Xixi Gui; Lei Zhou; Xinna Ge; Xin Guo; John W Wills; Jun Han; Hanchun Yang
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

5.  Molecular association of herpes simplex virus type 1 glycoprotein E with membrane protein Us9.

Authors:  Sita Awasthi; Harvey M Friedman
Journal:  Arch Virol       Date:  2016-08-27       Impact factor: 2.574

6.  A bovine herpesvirus type 1 mutant virus specifying a carboxyl-terminal truncation of glycoprotein E is defective in anterograde neuronal transport in rabbits and calves.

Authors:  Z F Liu; M C S Brum; A Doster; C Jones; S I Chowdhury
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

7.  Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry.

Authors:  Barbara Berarducci; Jaya Rajamani; Mike Reichelt; Marvin Sommer; Leigh Zerboni; Ann M Arvin
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

8.  The amino terminus of varicella-zoster virus (VZV) glycoprotein E is required for binding to insulin-degrading enzyme, a VZV receptor.

Authors:  Qingxue Li; Tammy Krogmann; Mir A Ali; Wei-Jen Tang; Jeffrey I Cohen
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

9.  Immunization strategies to block the herpes simplex virus type 1 immunoglobulin G Fc receptor.

Authors:  Xiaoqing Lin; John M Lubinski; Harvey M Friedman
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging.

Authors:  Elizabeth R Sprague; Chu Wang; David Baker; Pamela J Bjorkman
Journal:  PLoS Biol       Date:  2006-05-02       Impact factor: 8.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.